IP Library Granted Patent US 8,003,317
Granted Patent B2
US 8,003,317 · App. 10/903,268 · Granted Aug 23, 2011

Methods for high level multiplexed polymerase chain reactions and homogeneous mass extension reactions

Assignee: Sequenom, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,003,317
App. No.
10/903,268
Granted
Aug 23, 2011
Kind
B2
Abstract

Provided herein are optimized methods for performing multiplexed detection of a plurality of sequence variations. Also provided are methods for performing multiplexed amplification of target nucleic acid.

Claims (38)

1. A multiplex method of genotyping a plurality of polymorphic loci, comprising:

(a) simultaneously amplifying a plurality of nucleic acid-target regions under amplification conditions whereby at least 60% of 7 or more nucleic acid target-regions attempted are amplified by 7 or more amplification primer pairs to produce an amplified mixture of nucleic acid-target regions containing polymorphic loci, wherein the amplification conditions comprise dNTPs;

(b) after (a) contacting the amplified mixture of nucleic acid-target regions with 7 or more genotyping primers in the presence of at least one chain terminating reagent under primer mass extension conditions whereby the primers are extended up to, or through, the respective polymorphic loci, wherein there is one genotyping primer for each polymorphic locus and wherein the extension conditions comprise at least 55 cycles;

(c) determining the mass of the extended genotyping primers; and

(d) determining at least 60% of the genotypes for said 7 or more nucleic acid target-regions attempted.

2. The method of claim 1 , wherein at least 70% of the attempted genotypes are determined.

3. The method of claim 1 , wherein at least 75% of the attempted genotypes are determined.

4. The method of claim 1 , wherein at least 85% of the attempted genotypes are determined.

5. The method of claim 1 , wherein at least 90% of the attempted genotypes are determined.

6. The method of claim 1 , wherein at least 95% of the attempted genotypes are determined.

7. The method of claim 1 , wherein at least 96%, 97%, 98%, 99% or 100% of the attempted genotypes are determined.

8. The method of claim 1 , wherein a sequence tag is attached to a quantity of primer pairs selected from 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, or 13 or more.

9. The method of claim 1 , wherein a sequence tag is attached to 15 or more primer pairs.

10. The method of claim 1 , wherein a sequence tag is attached to 16 or more primer pairs.

11. The method of claim 1 , wherein a sequence tag is attached to 18 or more primer pairs.

12. The method of claim 1 , wherein only a single primer pair is utilized to amplify each particular nucleic acid target-region.

13. The method of claim 1 , wherein the amplification-reaction conditions comprise water, genomic DNA, a buffer, dNTPs, the primer pairs, MgCl 2 , and a polymerase, wherein the ratio of the concentration of MgCl 2 to the concentration of each one of the dNTPs is selected from ≦0:1, ≦9:1, ≦8:1, ≦7:1, ≦6:1, or ≦5:1.

14. The method of claim 13 , wherein the polymerase is Taq polymerase at a concentration of 0.03 units/μl.

15. The method of claim 1 , wherein the amplification-reaction conditions comprise between about 400-700 μM of each dNTP, about 100 nM primer pairs, and between about 2.6 up to about 4.8 mM MgCl 2 .

16. The method of claim 1 , wherein 13 or more primer pairs and 13 or more genotyping primers are utilized to genotype 13 or more nucleic acid target-regions.

17. The method of any of claim 16 , whereby at least 90% of the nucleic acid target-regions attempted are amplified.

18. The method of claim 1 , wherein at least 30 or more nucleic acid target-regions attempted are amplified by 30 or more primer pairs.

19. The method of any of claim 18 , whereby at least 90% of the nucleic acid target-regions attempted are amplified.

20. The method of claim 1 , wherein a sequence tag is attached to a primer in a primer pair.

21. The method of claim 1 , wherein the extension conditions comprise at least 65 cycles.

22. The method of claim 1 , wherein the extension conditions comprise at least 100 cycles.

23. The method of claim 1 , wherein the concentration of each genotyping primer is selected to even out the mass intensities of the extended genotyping primers.

24. The method of claim 1 , wherein each genotyping primer is selected so that the masses of the extended products and primers do not overlap.

25. The method of claim 1 , further comprising a free Mg 2+ concentration between 1.0-2.0 mM.

26. The method of claim 1 , wherein the extension conditions comprise 60 or more cycles.

27. The method of claim 1 , wherein the extension conditions comprise 70 or more cycles.

28. The method of claim 1 , wherein the extension conditions comprise 80 or more cycles.

29. The method of claim 1 , further comprises inactivating one or more amplifiation reactants.

30. The method of claim 29 , wherein the one or more amplification reactants includes a nucleotide.

31. The method of claim 30 , wherein the nucleotide is inactivated by a phosphatase.

32. The method of claim 29 , wherein the one or more amplification reactants includes a primer.

33. The method of claim 32 , wherein an primer is inactivated by a nuclease.

34. The method of claim 33 , wherein the nuclease is an exonuclease.

Assignments (9)
SECURITY INTEREST Recorded Dec 10, 2021
From: AGENA BIOSCIENCE, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 058358/0661 →
RELEASE OF SECURITY INTEREST Recorded Dec 7, 2021
From: MIDCAP FUNDING IV TRUST
To: AGENA BIOSCIENCE, INC.
Reel/Frame 058741/0005 →
RELEASE OF SECURITY INTEREST IN REEL 041621 FRAME 0548 Recorded Jul 13, 2021
From: MIDCAP FINANCIAL TRUST
To: AGENA BIOSCIENCE, INC.
Reel/Frame 056860/0557 →
SECURITY INTEREST Recorded Mar 21, 2017
From: AGENA BIOSCIENCE, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 042050/0888 →
SECURITY INTEREST Recorded Feb 3, 2017
From: AGENA BIOSCIENCE, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 041621/0548 →
CHANGE OF NAME Recorded Jun 27, 2014
From: BIOSCIENCES ACQUISITION COMPANY
To: AGENA BIOSCIENCE, INC.
Reel/Frame 033248/0073 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2014
From: SEQUENOM, INC.
To: BIOSCIENCES ACQUISITION COMPANY
Reel/Frame 033182/0062 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2004
From: BEAULIEU, MARTIN; VAN DEN BOOM, DIRK
To: SEQUENOM, INC.
Reel/Frame 015470/0521 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2004
From: BEAULIEU, MARTIN; VAN DEN BOOM, DIRK JOHANNES
To: SEQUENOM, INC.
Reel/Frame 015434/0202 →
Continuity (2)
Provisional Application 60492102 · Jul 31, 2003
Related Publication 20050079521A1 · Apr 14, 2005